Povetacicept reduces disease activity in MG mouse model
Povetacicept, a treatment for autoimmune diseases in the pipeline of Vertex Pharmaceuticals, reduced disease activity in a study with a mouse model of myasthenia gravis (MG) by lowering the levels of disease-causing antibodies in the bloodstream. Researchers also observed that povetacicept outperformed efgartigimod — approved as Vyvgart…